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ABSTRACT: A facile one pot synthesis of 2-styrylindoles, through Suzuki-arylation of ortho-substituted chloroenynes 
followed by N-cyclization and N-demethylation has been developed. A variety of 2-styrylindoles were obtained in good to 
excellent yields and were evaluated for their anticancer properties. 
1. INTRODUCTION 
Combretastatin A-4 (CA-4, Fig. 1) is a (Z)-stilbene 
isolated in 1989 by Pettit from the South African willow 
tree Combretum caffrum.1  
 
FIGURE 1. CA-4 and structural analogues  
This natural compound exhibited strong antitumor 
properties as for example, a nanomolar level of 
cytotoxicity against a variety of cancer cell lines 
including multi-drugs resistant cells.2 Moreover at very 
low doses, CA-4 inhibited tubulin assembly by binding at 
the colchicine binding-site,3 induced apoptosis4 and 
caused in vivo spectacular vascular shutdown in 
established tumors.5 In 2016, CA-4P (fosbretabulin), a 
phosphate water-soluble prodrug of the natural product 
has received the status of orphan drug in USA and 
Europe for the treatment of ovarian cancers, 
neuroendocrine tumours, certain thyroid cancers and 
multiform glioma.6 Despite these excellent antitumor 
properties, CA-4 has some drawbacks as a poor water-
solubility and a chemical instability due to the 
isomerization of the Z-double bond to its less active E-
form during storage, administration7 and metabolism.8 
Due to the simplicity of its chemical structure, CA-4 has 
been extensively studied to find more stable analogues 
and to establish structure-activity relationships (SARs).9 
As a part of our research program dedicated to novel 
stable vascular disrupting agents (VDAs)10 having a non-
isomerizable spacer between A- and B-rings, we found 
that isoCA-4,10d isoerianin11 and azaFiso-erianin12 
derivatives were as potent as CA-4 with comparable 
anticancer activities (Fig. 1). Moreover, if the 
replacement of the 3,4,5-trimethoxyphenyl A-ring of CA-
4 has received little attention,13 the B-ring of CA-4 has 
been subject to numerous modifications and can be 
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replaced for example, by a variety of indole nuclei with 
no loss of biological properties.14 For examples, it was 
recently showed that non-substituted N-methylindoles12 
and 3-substituted indoles14 replaced with a certain 
success the traditional phenolic B-ring of CA-4. To our 
knowledge, introduction of styryl substituents on the C-2 
position of the indole B-ring and their effects on 
biological activity was not reported in the CA-4 and 
isoCA-4 series. 
Due to the synthetic and biological interest for 2-
alkenylindoles,15 their preparations have been well 
studied16 and often, involve the alkenylation of pre-
formed indoles by C-H functionalization17 or by Suzuki-
Miyaura coupling reactions.18 Otherwise, 2-styrylindoles 
have also been prepared from 5-endo-dig-cyclizations of 
2-alkynylanilines having a free NH2 function by 
electrochemistry or using various metal catalysts.19 
Herein, we would like to present a novel and rapid access 
to 2-alkenylindoles from an efficient “one pot” Suzuki 
arylation–heterocyclization-N-demethylation process. 
N,N-Dimethylanilines having on ortho-position a 
conjugated chloroenyne moiety were firstly arylated 
using different boronic acids in the presence of a catalytic 
amount of Pd(PPh3)4 which was re-used for the 
cyclization-step to furnish a small library of 2-styryl 
indoles after N-demethylation. After optimization of this 
“one pot” three-step process, the cytotoxicity of novel 2-
styrylindoles 1 and 2 having a trimethoxyphenyl A-ring 
will be discussed. 
2. RESULTS AND DISCUSSION 
The required starting material, (E)-2-(4-chlorobut-3-en-1-
yn-1-yl)-N,N-dimethylaniline 3a, used as a model 
substrate, was readily prepared by the Sonogashira 
coupling of 2-ethynyl-N,N-dimethylaniline with (E)-1,2-
dichloroethylene in 78 %. Since the treatment of 
chloroenyne 3 with boronic acids in the presence of 
suitable Pd-catalysts would lead to diarylated enynes20 4 
intermediates, we anticipated that the Pd species might 
activated the alkyne triple bond of intermediates 4 to 
provide 2-styrylindoles 5 after N-cyclization and 
ammonium demethylation. To identify suitable 
conditions for this transformation, we evaluated the 
Suzuki arylation / cyclization / N-demethylation reaction 
with (E)-chloroenyne 3a in the presence of (4-acetyl) 
phenylboronic acid and a variety of Pd-catalysts. The 
result of this study is reported in Table 1. 
TABLE 1: Optimization of the tandem Suzuki-Miyaura cyclization reaction between (E)-3 and (4-acetylphenyl) boronic 
acida 
 
 
Entry [Pd] 3 x Time 
(h) 
4 Yield of 
(E)-4 (%)b 
5 Yield of 
(E)-5 (%)b 
1 Pd(PPh3)4 3a 5 15 4a 46 5a 43 
2 Pd(dba)2  5 15  ndc  ndc 
3 PdCl2(PhCN)2  5 15  ndc  ndc 
4 PdCl2(dppf)  5 15  ndc  ndc 
5 XantPhos Pd G3  5 15  ndc  ndc 
6 Pd(PPh3)4  8 15  32  55 
7 Pd(PPh3)4  8 30  21  67 
8 Pd(PPh3)4  8 48  0  90 
9 Pd(PPh3)4 3b 8 48 4b ndc 5b ndc 
10 Pd(PPh3)4 3c 8 48 4c ndc 5c ndc 
11 Pd(PPh3)4 3d 8 48 4d ndc 5d ndc 
aConditions: (E)-3 (0.5 mmol), (4-acetyl)boronic acid (0.65 mmol), [Pd] (x mmol), K2CO3 (2 equiv) and toluene/MeOH (2:1) (9 mL) were 
heated in a sealed tube at 90 °C for time indicated in Table 1 under an argon atmosphere. bYield of isolated product. c Complex mixture of 
compounds. 
Initially, we have tested the conditions developed in our 
laboratory for the coupling of boronic acids with 
chloroenynes20 using Pd(PPh3)4 (5 mol %) as the catalyst, 
K2CO3 (2 equiv) as the base, and toluene/MeOH (2:1) as 
the solvent combination at 90 °C in a sealed tube (entry 
1). After 15 h of stirring and disappearance of 
chloroenyne (E)-3a, we isolated the desired indole (E)-5a 
together with diarylenyne (E)-4a in almost similar yields. 
This promising first result, confirming our initial 
hypothesis, led us to evaluate other Pd-catalysts to 
improve the cyclization reaction of the (E)-4a 
intermediate. Unfortunately, as depicted in entries 2-5, 
none of the Pd(0), Pd(II) catalysts as well as the third 
generation (G3) Buchwald pre-catalyst were able to 
transform (E)-3a into indole (E)-5a which was not 
detected in crude mixtures after 15 h of reaction. It is 
likely that under these conditions, the Suzuki-arylation 
reaction leading to 4a did not occur and that (E)-3a was 
completely degraded. We then decided to increase the 
amount of Pd(PPh3)4 quantity from 5 to 8 mol %, and we 
were pleased to observe the formation of indole (E)-5a, 
as the main product (90 %) after 48 h of reaction (entry 
8). Further screening of solvents, solvent combinations 
and bases associated to Pd(PPh3)4 were less effective for 
2-styrylindole (E)-5a generation. We also examine the 
efficiency of this process, under our optimized 
conditions, with arylated chloroenynes 3b-d (entries 9-
11) having on ortho-position a free-NH2 (3b), a 
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secondary amine (NHMe, 3c) or a NH-tosylamine (3d). 
In contrast to (E)-3a, none of chloroenynes 3b-d were 
able to provide the desired corresponding indole 
derivatives which were not detected in the crude complex 
mixtures. Using 8 mol% of Pd(PPh3)4 in the presence of 
2 equiv of K2CO3 in hot toluene/MeOH mixture, 
chloroenyne (E)-3a reacted with various boronic acids to 
generate a number of 2-styrylindoles 5a-l. As depicted in 
Figure 2, the reaction exhibits excellent scope: both 
electron-deficient and electron-rich arylboronic acids 
reacted efficiently to provide the desired 2-styryl indoles 
with high to excellent yields for this three-step “one-pot” 
reaction (from 71 to 92%). 
 
FIGURE 2. Tandem Suzuki-Miyaura cyclization reaction of (E)-chloroenyne 3a using a variety of arylboronic acids. 
Substitutions are readily tolerated at all positions of the 
arylboronic acid substrates to provide the 2-styrylindoles 
in similar yields (5f-h). Introduction of heterocycles on 
the double bond is also permitted with this protocol since 
5l was obtained in a good yield of 86 % using 2-
benzothiophene boronic acid as the nucleophile. The 
following mechanism depicted in Scheme 1 can be 
considered.  
SCHEME 1. Plausible mechanism for the synthesis of 
styrylindoles 5 from chloroenyne (E)-3a. 
 
A plausible mechanism is depicted in Scheme 1 
involving the formation of an indolinium salt according 
to a 5-endo-dig cyclization of diarylenyne 4.21 Then, a N-
demethylation step of the indolinium by MeOH leads to 
styrylindole 5 and dimethylether.22 
Next, as part of our medicinal chemistry project, we next 
have synthesized N,N-dimethylaniline (E)-3e having a 
chloroenyne group on ortho-position and on para-
position a 1-(3,4,5-trimethoxyphenyl)vinyl moiety as the 
future A-ring (Scheme 2). 
A Pd-catalyzed reaction of trimethylsilylacetylene with 4-
bromo-2-iodo-N,N-dimethylaniline afforded trimethyl 
silylated (TMS)-alkyne 6 according to a Sonogashira 
coupling reaction (91%). 
 
SCHEME 2. Synthesis of (E)-3e.a 
aConditions: (i) ArI (20 mmol), alkyne (22 mmol), PdCl2(PPh3)2 (5 
mol %), CuI (10 mol %), Et3N, rt. (ii) 7 (12 mmol), 6 (10 mmol), 
Pd2dba3 (5 mol %), Xphos (10 mol %), LiOtBu (2.2 equiv), 
dioxane, 70 °C. (iii) K2CO3, MeOH, rt. (iv) (E)-1,2-
dichloroethylene (10 equiv), PdCl2(PPh3)2 (5 mo%), CuI (10 mol 
%), piperidine (2 equiv), Et2O, rt. 
Then, by using a recent methodology developed by 
Barluenga and co-workers,23 diarylethylene derivative 8 
was synthesized in a good yield of 86% through the 
palladium coupling reaction of N-tosylhydrazone 7 with 6 
using Pd2dba3 as the catalyst, Xphos as the ligand and 
LiOtBu as the base in hot dioxane. Under these basic 
conditions, we were surprised to observe that the TMS 
group of 8 remained unchanged and was finally 
deprotected under classical conditions using K2CO3 in 
MeOH to give 9 (92%). A further Sonogashira-
Linstrumelle coupling reaction with (E)-1,2-
dichloroethylene furnished (E)-3e (76%) as a useful 
platform to introduce a variety of styryl groups on the C-
2 position of novel substituted indole derivatives after 
Pd-catalyzed arylation-cyclization reactions (Figure 3). 
By applying our optimized protocol developed for the 
tandem arylation-cyclization of chloroenyne (E)-3 with 
boronic acids, we prepared the desired indole derivatives 
(E)-1a-g in moderate yields due to difficulties 
encountered during the purification step. 
Next, to synthesize a series of azaisoerianin analogues 
(E)-2a-d of biological interest, 3,4,5-trimethoxy-N-
methylaniline was coupled with alkyne 6 under Pd-
catalysis to give tertiary amine 10 (83%). After a 
desilylation step of the alkyne function of 10, the 
resulting terminal alkyne 11 (90%) was then coupled 
with (E)-1,2-dichloroethylene to give (E)-3f in an 
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acceptable yield of 66%. This later was then transformed 
into the desired indoles 2a-d using this novel Suzuki-
cyclization-N-demethylation process with good yields 
(from 74% to 82%) for the three steps (Scheme 3). 
In vitro cytotoxicity of the newly synthesized indole 
derivatives 1 and 2 was investigated against HCT116, a 
human colon carcinoma cell line. A colorimetric-based 
assay was used to determine the drug concentration 
required to inhibit cell growth by 50% (GI50) after 
incubation in the culture medium for 72 h. IsoCA-4 was 
included as the reference for comparisons. The screening 
revealed that all newly synthesized indole derivatives 1 
and 2 evaluated against HCT cancer cell lines displayed 
an average level of cytotoxicity when compared with 
isoCA-4 (Table 2). The comparison of the GI50 values 
obtained for compounds 1 and 2 clearly revealed that 1,1-
diarylethylenes derivatives 1a-g displayed a promising 
sub-micromolar level of cytotoxicity (0.18 M < GI50 < 
0.74 M) whereas their N-Methyl analogues 2a-d 
displayed a lower level of cytotoxicity with GI50 values 
ranging from 1.32 to 4.08M. The cytotoxic of promising 
derivatives 1c and 1e having respectively a p-methoxy 
and a m-NO2 group on their aromatic rings displayed 
encouraging GI50 values (0.26 M for 1c and 0.18 M 
for1e.) will be furthermore modified in our lab in view of 
possible improvements of cytotoxicity against a range 
human cancer cell lines. 
 
FIGURE 3. Tandem Suzuki-cyclization reaction of (E)-
chloroenyne 3e using a variety of arylboronic acids. 
 
SCHEME 3. Synthesis of (E)-2a-d. 
aConditions: (i) ArBr (1 mmol), 3,4,5-trimethoxy-N-methylaniline (1.2 mmol), Pd2dba3 (5 mol %), Xphos (10 mol %), NaOtBu (2.2 equiv), 
toluene, 70 °C. (ii) K2CO3, MeOH, rt. (iii) (E)-1,2-dichloroethylene (10 equiv), PdCl2(PPh3)2 (5 mo%), CuI (10 mol %), piperidine (5 equiv), 
Et2O, rt. (iv) (E)-3f (0.5 mmol), boronic acid (0.65 mmol), Pd(PPh3)4 (8 mol%), K2CO3 (2 equiv) were diluted in in toluene/MeOH (2:1) (9 mL) 
and placed in a sealed tube and heated at 90 °C. 
TABLE 2. Cytotoxicity against HCT116 cellsa and ITP of indoles 1a-g and 2a-d. 
Compound (E)-1a (E)-1b (E)-1c (E)-1d (E)-1e (E)-1f 
Cytotoxicity GI50b 
[M] 
0.74 ± 0.17 0.43 ± 0.21 0.26 ± 0.02 0.37 ± 0.04 0.18 ± 0.06 0.52 ± 0.07 
% of inhibition at 
100 M 
21 31 23 37 26 56 
Compound (E)-1g (E)-2a (E)-2b (E)-2c (E)-2d isoCA-4 
Cytotoxicity GI50b 
[M] 
0.54 ± 0.03 1.90 ± 0.67 1.32 ± 0.32 1.84 ± 0.27 4.08 ± 0.41 0.002 
% of inhibition at 
100 M 
40 35 36 83 19 1.0 ± 0.1c 
aHCT-116 Human colon carcinoma. bGI50 is the concentration of compound needed to reduce cell growth by 50% following 72 h cell treatment 
with the tested drug (average of three experiments). cGI50 is the concentration of isoCA-4 required to inhibit 50% of the rate of microtubule 
assembly (average of three experiments). 
To examine if the cytotoxicity of compounds 1 and 2 was 
related to an interaction with the microtubule system, 
indoles 1 and 2 were next evaluated in tubulin assembly 
assays in parallel with isoCA-4 (Table 2). However, 1c 
and 1e which displayed the best cytotoxicity level 
against HCT116 cells inhibited tubulin assembly with 
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modest GI50 values comparable to the GI50 of all other 
indole derivatives 1 and 2. Currently, we are working to 
improve the cytotoxicity of derivatives 1 through the 
introduction of more suitable substituents. 
3. CONCLUSION 
In summary, we have discovered a novel 3-steps Suzuki-
Miyaura arylation / cyclization / N-demethylation of (E)-
2-(4-chlorobut-3-en-1-yn-1-yl)-N,N-dimethylanilines, gi-
ving an efficient and rapid access to 2-styrylindoles with 
good to excellent yields. Using this strategy, we have 
rapidly achieved the synthesis of a series of 1,1-
diarylethylenes 1 and diarylmethylamines 2 bearing a 
3,4,5-trimethoxyphenyl core and various functionalized 
2-styrylindoles as isoCA-4 and azaisoerianin analogues. 
From the preliminary biological results, indoles 1c and 1e 
were the most promising compounds with nanomolar 
GI50 values. Structural modifications on the indole 
nucleus are currently under study in our laboratory and 
will be published later. 
4. EXPERIMENTAL SECTION 
General Information and Method. All glasswares were 
oven-dried at 140 °C and all reactions were conducted 
under an argon atmosphere. Solvents: cyclohexane, ethyl 
acetate (EtOAc), for chromatography, were technical 
grade. The 1H NMR and 13C NMR and 19F spectra were 
recorded in CDCl3, acetone-d6 or DMSO-d6 on Bruker 
Avance 300 spectrometer. The chemical shifts of 1H are 
reported in ppm relative to the solvent residual peak in 
CDCl3 (δ 7.26), acetone-d6 (δ 2.05), DMSO-d6 (δ 2.50) 
for 1H NMR. For the 13C NMR spectra, the solvent 
signals of CDCl3 (δ 77.14), acetone-d6 (δ 206.26), 
DMSO-d6 (δ 39.52) were used as the internal standards. 
The following abreviation are used: m (multiplet), s 
(singlet), d (doublet), t (triplet), dd (doublet of doublet), 
td (triplet of doublet), ddd (doublet of doublet of 
doublet). IR spectra were measured on a Bruker Vector 
22 spectrophotometer (neat, cm-1). High-resolution mass 
spectra were recorded on a Bruker Daltonics micrOTOF-
Q instrument. Analytical TLC was performed on Merck 
precoated silica gel 60 F-254 plates. Merck silica gel 60 
(230-400 mesh) was used for column chromatography. 
The plates were visualized by either UV light (254 nm), 
or by a solution of phosphomolybdic acid in ethanol. 
General procedure for the synthesis of (E)-
chloroenynes 3a, 3b, 3e, 3f. 
To a solution of alkyne (5 mmol) in Et2O (30 mL) was 
added successively (E)-1,2-dichloroethylene (4 mL, 50 
mmol), PdCl2(PPh3)2 (175 mg, 0.25 mmol), piperidine (1 
mL, 10 mmol) and CuI (95 mg, 0.5 mmol). After 
complete disappearance of starting material monitored by 
TLC, the solution was filtered through a pad of celite 
using EtOAc. The organic layer was washed successively 
with sat. NH4Cl, sat. NaHCO3 and HCl (1 M) solutions. 
After drying over MgSO4 and evaporation in vacuo, the 
crude residue was purified by silica gel column 
chromatography (0 to 30% AcOEt in cyclohexane) (the 
crude of 3g was purified on neutral Al2O3). 
(E)-2-(4-Chlorobut-3-en-1-yn-1-yl)-N,N-dimethyl 
aniline (3a) 
Brown solid, mp 36.8 – 37.0 °C, yield 78%, 802 mg. 
1H NMR (300 MHz, CDCl3) δ = 7.52 (dd, J = 7.5 Hz, J = 
1.2 Hz, 1H), 7.28 (td, J = 7.5 Hz, J = 1.2 Hz, 1H), 6.97 – 
6.86 (m, 2H), 6.63 (d, J = 13.5 Hz, 1H), 6.25 (d, J = 13.5 
Hz, 1H), 2.95 (s, 6H). 13C{1H} NMR (75 MHz, CDCl3) δ 
= 154.9 (Cq), 134.3 (CH), 129.7 (CH), 129.2 (CH), 120.7 
(CH), 117.1 (CH), 114.6 (Cq), 114.4 (CH), 91.5 (Cq), 
89.7 (Cq), 43.6 (2 CH3). IR (neat): 2945, 2197, 1595, 
1325, 1049, 1011 cm-1. HRMS (ESI): m/z [M+H]+ calcd 
for C12H13N35Cl: 206.0737; found: 206.0735. 
(E)-2-(4-Chlorobut-3-en-1-yn-1-yl)aniline (3b) 
Brown oil, yield 79%, 702 mg. 
1H NMR (300 MHz, CDCl3) δ = 7.16 (d, J = 7.5 Hz, 1H), 
7.01 (t, J = 8.1 Hz, 1H), 6.61 – 6.45 (m, 3H), 6.08 (d, J = 
13.5 Hz, 1H), 4.01 (br, 2H). 13C NMR (75 MHz, CDCl3) 
δ = 147.9 (Cq), 132.1 (CH), 130.1 (CH), 129.6 (CH), 
118.0 (CH), 114.4 (CH), 113.8 (CH), 107.2 (Cq), 89.6 
(Cq), 88.7 (Cq). IR (neat): 3479, 3384, 2194, 1699, 1488, 
1314 cm-1. HRMS (ESI): m/z [M+H]+ calcd for 
C10H9N35Cl: 178.0424; found: 178.0424. 
(E)-2-(4-Chlorobut-3-en-1-yn-1-yl)-N,N-dimethyl-4-(1-
(3,4,5-trimethoxyphenyl)vinyl)-aniline (3e) 
Brown oil, yield 76%, 1.51 g. 
1H NMR (300 MHz, acetone-d6) δ = 7.36 (d, J = 2.1 Hz, 
1H), 7.26 (dd, J = 8.7 Hz, J = 2.1 Hz, 1H), 6.91 (d, J = 
8.7 Hz, 1H), 6.82 (d, J = 13.5 Hz, 1H), 6.62 (s, 2H), 6.33 
(d, J = 13.5 Hz, 1H), 5.38 (s, 1H), 5.35 (s, 1H), 3.79 (s, 
6H), 3.77 (s, 3H), 2.97 (s, 6H). 13C{1H} NMR (75 MHz, 
CDCl3) δ = 159.1 (Cq), 157.9 (2 Cq), 153.1 (Cq), 142.6 
(Cq), 141.7 (Cq), 138.3 (CH), 137.1 (Cq), 135.2 (CH), 
134.6 (CH), 121.9 (CH), 119.4 (CH), 118.3 (CH2), 117.3 
(Cq), 110.8 (2 CH), 96.7 (Cq), 94.8 (Cq), 65.2 (CH3), 
61.1 (2 CH3), 47.9 (2 CH3). IR (neat): 2937, 2196, 1579, 
1502, 1347, 1235 cm-1. HRMS (ESI): m/z [M+H]+ calcd 
for C23H25NO335Cl: 398.1523; found: 398.1523. 
(E)-2-(4-Chlorobut-3-en-1-yn-1-yl)-N1,N1,N4-trimethyl 
-N4-(3,4,5-trimethoxyphenyl)-benzene-1,4-diamine (3f) 
Brown oil, yield 66%, 1.32 g. 
1H NMR (300 MHz, acetone-d6) δ = 7.09 – 6.90 (m, 3H), 
6.83 (d, J = 13.5 Hz, 1H), 6.34 (d, J = 13.5 Hz, 1H), 6.25 
(s, 2H), 3.75 (s, 6H), 3.69 (s, 3H), 3.23 (s, 3H), 2.86 (s, 
6H). 13C{1H} NMR (75 MHz, acetone-d6) δ = 154.8 (2 
Cq), 150.8 (Cq), 146.6 (Cq), 143.8 (Cq), 134.2 (Cq), 
130.1 (CH), 127.0 (CH), 124.1 (CH), 119.1 (CH), 116.2 
(Cq), 115.2 (CH), 98.9 (2 CH), 92.4 (Cq), 89.9 (Cq), 
60.6 (CH3), 56.4 (2 CH3), 43.9 (2 CH3), 40.9 (CH3). IR 
(neat): 2937, 2197, 1585, 1496, 1235, 1128 cm-1. HRMS 
(ESI): m/z [M+H]+ calcd for C22H26N2O335Cl: 401.1632; 
found: 401.1639. 
Procedure for the synthesis of (E)-chloroenynes 3c. 
To a solution of 3b (5 mmol, 888 mg) in DMF (30 mL) 
was added K2CO3 (1.5 equiv) and iodomethane (1.1 
equiv). The reaction was stirred at room temperature for 
3 h then quenched with water (30 mL). The aqueous layer 
was extracted with CH2Cl2 three times and the combined 
organic extracts were dried with anhydrous MgSO4, 
filtered and concentrated. The crude mixture was purified 
by silica gel column chromatography (0 to 30% AcOEt in 
cyclohexane). 
(E)-2-(4-Chlorobut-3-en-1-yn-1-yl)-N-methylaniline 
(3c) 
Brown oil, yield 48%, 460 mg. 
1H NMR (300 MHz, CDCl3) δ = 7.22 – 7.10 (m, 2H), 
6.63 – 6.44 (m, 3H), 6.11 (d, J = 13.8 Hz, 1H), 4.46 (br, 
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1H), 2.80 (s, 3H). 13C{1H} NMR (75 MHz, CDCl3) δ = 
149.9 (Cq), 132.2 (CH), 130.5 (CH), 129.5 (CH), 116.4 
(CH), 114.0 (CH), 109.2 (CH), 106.7 (Cq), 89.9 (Cq), 
88.9 (Cq), 30.3 (CH3). IR (neat): 3421, 3071, 2191, 1510, 
1320 cm-1. HRMS (ESI): m/z [M+H]+ calcd for 
C11H11N35Cl: 192.0580; found: 192.0570. 
Procedure for the synthesis of (E)-chloroenynes 3d. 
A solution of 4-methylbenzene-1-sulfonyl chloride (1 
equiv) in THF (20 mL) was added dropwise over 0.5 h to 
a solution of 3b (5 mmol) and pyridine (1.1 equiv) in 
THF (30 mL) under argon. The solution was stirred at r.t. 
for 12 h. The resulting mixture was evaporated under 
vacuum and the residue was purified by silica gel column 
chromatography (0 to 30% AcOEt in cyclohexane). 
(E)-N-(2-(4-Chlorobut-3-en-1-yn-1-yl)phenyl)-4-
methylbenzenesulfonamide (3d) 
White solid, mp 125.6 – 125.9 °C, yield 63%, 1.05 g. 
1H NMR (300 MHz, CDCl3) δ = 7.68 (d, J = 8.4 Hz, 2H), 
7.59 (d, J = 8.4 Hz, 1H), 7.33 – 7.22 (m, 4H), 7.10 – 7.01 
(m, 2H), 6.63 (d, J = 13.8 Hz, 1H), 6.13 (d, J = 13.8 Hz, 
1H), 2.39 (s, 3H). 13C{1H} NMR (75 MHz, CDCl3) δ = 
144.2 (Cq), 137.7 (Cq), 136.2 (Cq), 132.2 (CH), 131.8 
(CH), 130.1 (CH), 129.7 (2 CH), 127.3 (2 CH), 124.7 
(CH), 120.4 (CH), 114.0 (Cq), 113.0 (CH), 90.9 (Cq), 
86.4 (Cq), 21.7 (CH3). IR (neat): 3074, 1489, 1396, 1159 
cm-1. HRMS (ESI): m/z [M+Na]+ calcd for 
C17H14NO2NaS35Cl: 354.0331; found: 354.0332. 
General procedure for the synthesis of 2-styrylindole 
5, 1, 2. 
Under argon, chloroenyne (0.5 mmol), the desired 
boronic acid (1.3 equiv), K2CO3 (2 equiv), and Pd(PPh3)4 
(8 mol%) were mixed in toluene (6 mL) and MeOH (3 
mL). The reaction mixture was stirred at 90°C in 30 mL 
sealed tube monitored by TLC (48 h). After the mixture 
were allowed to cool to room temperature and filtrated 
through a pad of celite washed by CH2Cl2. Solvent was 
removed under reduced pressure and the crude material 
was purified by silica gel column chromatography (0 to 
30% AcOEt in cyclohexane). 
(E)-1-(4-(2-(1-Methyl-1H-indol-2-yl)vinyl)phenyl) 
ethan-1-one (5a) 
Yellow solid, mp 188.5 – 188.9 °C, yield 90%, 123.9 mg. 
1H NMR (300 MHz, CDCl3) δ = 7.99 (d, J = 8.4 Hz, 2H), 
7.65 – 7.60 (m, 3H), 7.36 – 7.11 (m, 5H), 6.90 (s, 1H), 
3.86 (s, 3H), 2.64 (s, 3H). 13C{1H} NMR (75 MHz, 
CDCl3) δ = 197.5 (Cq), 141.9 (Cq), 138.5 (Cq), 137.8 
(Cq), 136.1 (Cq), 129.3 (CH), 129.1 (2 CH), 128.0 (Cq), 
126.5 (2 CH), 122.4 (CH), 120.8 (CH), 120.2 (CH), 
119.7 (CH), 109.4 (CH), 100.2 (CH), 30.1 (CH3), 26.7 
(CH3). IR (neat): 3054, 1675, 1597, 1348, 1274 cm-1. 
HRMS (ESI): m/z [M+H]+ calcd for C19H18NO: 
276.1388; found: 276.1378. 
(E)-2-(4-Fluorostyryl)-1-methyl-1H-indole (5b) 
Yellow solid, mp 155.5 – 155.8 °C, yield 88%, 110.6 mg. 
1H NMR (300 MHz, DMSO-d6) δ = 7.77 – 7.71 (m, 2H), 
7.54 – 6.99 (m, 8H), 6.86 (s, 1H), 3.85 (s, 3H). 13C{1H} 
NMR (75 MHz, DMSO-d6) δ = 161.7 (d, J = 243.5 Hz, 
Cq), 138.2 (Cq), 137.7 (Cq), 133.6 (d, J = 2.0 Hz, Cq), 
129.0 (CH), 128.4 (d, J = 8.0 Hz, 2 CH), 127.4 (Cq), 
121.3 (CH), 119.8 (CH), 119.5 (CH), 117.2 (CH), 115.6 
(d, J = 21.4 Hz, 2 CH), 109.7 (CH), 98.1 (CH), 29.7 
(CH3). 19F NMR (188 MHz, DMSO-d6): δ = - 114.1. IR 
(neat): 1531, 1470, 1349, 1247, 1157 cm-1. HRMS (ESI): 
m/z [M+H]+ calcd for C17H15NF: 252.1189; found: 
252.1190. 
(E)-2-(4-Chlorostyryl)-1-methyl-1H-indole (5c) 
Yellow solid, mp 127.6 – 127.9 °C, yield 90%, 120.5 mg. 
1H NMR (300 MHz, DMSO-d6) δ = 7.72 (d, J = 8.4 Hz, 
2H), 7.55 – 7.41 (m, 5H), 7.29 (d, J = 16.2 Hz, 1H), 7.13 
(t, J = 7.5 Hz, 1H), 7.02 (t, J = 7.5 Hz, 1H), 6.89 (s, 1H), 
3.86 (s, 3H). 13C{1H} NMR (75 MHz, DMSO-d6) δ = 
138.0 (Cq), 137.8 (Cq), 136.0 (Cq), 131.9 (Cq), 128.8 
(CH), 128.6 (2 CH), 128.2 (2 CH), 127.4 (Cq), 121.4 
(CH), 119.9 (CH), 119.6 (CH), 118.2 (CH), 109.7 (CH), 
98.5 (CH), 29.7 (CH3). IR (neat): 1532, 1443, 1320, 1248 
cm-1. HRMS (APCI): m/z [M+H]+ calcd for C17H15N35Cl: 
268.0888; found: 268.0891. 
(E)-1-Methyl-2-(3-nitrostyryl)-1H-indole (5d) 
Yellow solid, mp 136.9 – 137.2 °C, yield 71%, 98.8 mg. 
1H NMR (300 MHz, CDCl3) δ = 8.26 (s, 1H), 7.99 (d, J = 
8.4 Hz, 1H), 7.67 (d, J = 7.5 Hz, 1H), 7.52 (d, J = 7.8 Hz, 
1H), 7.42 (t, J = 7.8 Hz, 1H), 7.23 – 7.01 (m, 5H), 6.77 
(s, 1H), 3.73 (s, 3H). 13C{1H} NMR (75 MHz, CDCl3) δ 
= 148.9 (Cq), 139.0 (Cq), 138.5 (Cq), 137.3 (Cq), 132.3 
(CH), 129.7 (CH), 127.9 (Cq), 127.8 (CH), 122.5 (CH), 
122.1 (CH), 120.8 (CH), 120.6 (CH), 120.3 (CH), 120.1 
(CH), 109.4 (CH), 100.4 (CH), 30.1 (CH3). IR (neat): 
1520, 1463, 1347, 1321 cm-1. HRMS (ESI): m/z [M+H]+ 
calcd for C17H15N2O2: 279.1134; found: 279.1125. 
(E)-4-(2-(1-Methyl-1H-indol-2-yl)vinyl)benzonitrile 
(5e) 
Yellow solid, mp 177.4 – 177.7 °C, yield 85%, 109.8 mg. 
1H NMR (300 MHz, DMSO-d6) δ = 7.95 – 7.77 (m, 4H), 
7.66 (d, J = 16.2 Hz, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.46 
(d, J = 8.4 Hz, 1H), 7.38 (d, J = 16.2 Hz, 1H), 7.16 (t, J = 
7.5 Hz, 1H), 7.04 (t, J = 7.5 Hz, 1H), 6.98 (s, 1H), 3.88 
(s, 3H). 13C{1H} NMR (75 MHz, DMSO-d6) δ = 141.8 
(Cq), 138.0 (Cq), 137.5 (Cq), 132.5 (2 CH), 128.1 (CH), 
127.3 (Cq), 127.1 (2 CH), 121.9 (CH), 121.0 (CH), 120.2 
(CH), 119.7 (CH), 119.1 (Cq), 109.9 (CH), 109.3 (Cq), 
99.6 (CH), 29.7 (CH3). IR (neat): 2223, 1599, 1463, 
1346, 1322 cm-1. HRMS (ESI): m/z [M+H]+ calcd for 
C18H15N2: 259.1235; found: 259.1246. 
(E)-2-(4-Methoxystyryl)-1-methyl-1H-indole (5f) 
Yellow solid, mp 141.4 – 141.8 °C, yield 92%, 121.1 mg. 
1H NMR (300 MHz, CDCl3) δ = 7.63 (d, J = 7.5 Hz, 1H), 
7.51 (d, J = 8.4 Hz, 2H), 7.34 – 7.12 (m, 4H), 7.05 (d, J = 
15.9 Hz, 1H), 6.96 (d, J = 8.4 Hz, 2H), 6.80 (s, 1H), 3.87 
(s, 3H), 3.83 (s, 3H). 13C{1H} NMR (75 MHz, CDCl3) δ 
= 159.5 (Cq), 138.8 (Cq), 138.1 (Cq), 130.6 (CH), 130.0 
(Cq), 128.1 (Cq), 127.7 (2 CH), 121.5 (CH), 120.3 (CH), 
119.8 (CH), 114.9 (CH), 114.2 (2 CH), 109.1 (CH), 98.4 
(CH), 55.4 (CH3), 29.9 (CH3). IR (neat): 1573, 1463, 
1395, 1247 cm-1. HRMS (ESI): m/z [M+H]+ calcd for 
C18H18NO: 264.1388; found: 264.1387. 
(E)-2-(3-Methoxystyryl)-1-methyl-1H-indole (5g) 
Yellow solid, mp 94.1 – 94.5 °C, yield 86%, 102.7 mg. 
1H NMR (300 MHz, CDCl3) δ = 7.65 (d, J = 8.1 Hz, 1H), 
7.43 – 7.06 (m, 8H), 6.94 – 6.82 (m, 2H), 3.91 (s, 3H), 
3.84 (s, 3H). 13C{1H} NMR (75 MHz, CDCl3) δ = 160.0 
(Cq), 138.7 (Cq), 138.4 (Cq), 138.2 (Cq), 130.8 (CH), 
129.8 (CH), 128.0 (Cq), 121.9 (CH), 120.5 (CH), 120.0 
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(CH), 119.2 (CH), 117.5 (CH), 113.4 (CH), 111.9 (CH), 
109.2 (CH), 99.2 (CH), 55.4 (CH3), 30.0 (CH3). IR 
(neat): 2936, 1597, 1577, 1433, 1319, 1284, 1157, 1010, 
952 cm-1. HRMS (ESI): m/z [M+H]+ calcd for C18H18NO: 
264.1388; found: 264.1390. 
(E)-1-Methyl-2-(3,4,5-trimethoxystyryl)-1H-indole (5h) 
Yellow solid, mp 180.2 – 180.3 °C, yield 78%, 126.1 mg. 
1H NMR (300 MHz, DMSO-d6) δ = 7.63 – 7.30 (m, 3H), 
7.23 (d, J = 16.2 Hz, 1H), 7.12 (t, J = 7.5 Hz, 1H), 7.05 -
6.95 (m, 3H), 6.83 (s, 1H), 3.87 (s, 3H), 3.86 (s, 6H), 
3.69 (s, 3H). 13C{1H} NMR (75 MHz, DMSO-d6) δ = 
153.0 (2 Cq), 138.4 (Cq), 137.7 (Cq), 137.4 (Cq), 132.7 
(Cq), 130.6 (CH), 127.5 (Cq), 121.2 (CH), 119.8 (CH), 
119.5 (CH), 116.6 (CH), 109.6 (CH), 104.1 (2 CH), 97.9 
(CH), 60.1 (CH3), 55.9 (2 CH3), 29.8 (CH3). IR (neat): 
2925, 1581, 1504, 1465, 1366 cm-1. HRMS (ESI): m/z 
[M+H]+ calcd for C20H22NO3: 324.1600; found: 
324.1600. 
(E)-2-(2,5-Dimethylstyryl)-1-methyl-1H-indole (5i) 
Yellow solid, mp 121.1 – 121.2 °C, yield 90%, 117.6 mg. 
1H NMR (300 MHz, DMSO-d6) δ = 7.63 (s, 1H), 7.56 – 
7.37 (m, 3H), 7.29 (d, J = 15.9 Hz, 1H), 7.16 – 7.08 (m, 
2H), 7.05 – 6.99 (m, 2H), 6.90 (s, 1H), 3.86 (s, 3H), 2.37 
(s, 3H), 2.33 (s, 3H). 13C{1H} NMR (75 MHz, DMSO-
d6) δ = 138.6 (Cq), 137.7 (Cq), 135.3 (Cq), 135.0 (Cq), 
132.4 (Cq), 130.3 (CH), 128.4 (CH), 127.8 (CH), 127.4 
(Cq), 125.5 (CH), 121.2 (CH), 119.8 (CH), 119.5 (CH), 
117.9 (CH), 109.7 (CH), 98.3 (CH), 29.7 (CH3), 20.7 
(CH3), 19.0 (CH3). IR (neat): 2921, 1463, 1319, 1236, 
1104, 954 cm-1. HRMS (ESI): m/z [M+H]+ calcd for 
C19H20N: 262.1596; found: 262.1597. 
(E)-1-Methyl-2-(4-vinylstyryl)-1H-indole (5j) 
Yellow solid, mp 157.6 – 157.8 °C, yield 89%, 115.4 mg. 
1H NMR (300 MHz, CDCl3) δ = 7.50 (d, J = 7.8 Hz, 1H), 
7.39 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 7.21 – 
6.99 (m, 5H), 6.72 (s, 1H), 6.63 (dd, J = 17.4 Hz, J = 
10.8 Hz, 1H), 5.69 (d, J = 17.6 Hz, 1H), 5.18 (d, J = 10.8 
Hz, 1H), 3.70 (s, 3H). 13C{1H} NMR (75 MHz, CDCl3) δ 
= 138.5 (Cq), 138.3 (Cq), 137.2 (Cq), 136.8 (Cq), 136.5 
(CH), 130.5 (CH), 128.1 (Cq), 126.7 (4 CH), 121.9 (CH), 
120.5 (CH), 120.0 (CH), 117.0 (CH), 114.0 (CH2), 109.2 
(CH), 99.2 (CH), 30.0 (CH3). IR (neat): 1530, 1462, 
1346, 1320, 907 cm-1. HRMS (ESI): m/z [M+H]+ calcd 
for C19H18N: 260.1439; found: 260.1445. 
(E)-1-Methyl-2-(2-(naphthalen-2-yl)vinyl)-1H-indole 
(5k) 
Yellow solid, mp 198.3 – 198.5 °C, yield 84%, 119.0 mg. 
1H NMR (300 MHz, DMSO-d6) δ = 8.20 – 7.80 (m, 5H), 
7.63 – 7.43 (m, 6H), 7.14 (t, J = 7.5 Hz, 1H), 7.03 (t, J = 
7.5 Hz, 1H), 6.94 (s, 1H), 3.90 (s, 3H). 13C{1H} NMR 
(75 MHz, DMSO-d6) δ = 138.3 (Cq), 137.8 (Cq), 134.6 
(Cq), 133.3 (Cq), 132.6 (Cq), 130.2 (CH), 128.1 (CH), 
127.8 (CH), 127.6 (CH), 127.5 (Cq), 126.5 (CH), 126.4 
(CH), 126.0 (CH), 123.7 (CH), 121.4 (CH), 119.9 (CH), 
119.6 (CH), 117.8 (CH), 109.7 (CH), 98.4 (CH), 29.7 
(CH3). IR (neat): 2923, 1463, 1342, 1320 cm-1. HRMS 
(ESI): m/z [M+H]+ calcd for C21H18N: 284.1439; found: 
284.1438. 
(E)-2-(2-(Benzo[b]thiophen-2-yl)vinyl)-1-methyl-1H-
indole (5l) 
Yellow solid, mp 203.7 – 203.8 °C, yield 86%, 124.4 mg. 
1H NMR (300 MHz, DMSO-d6) δ = 7.96 – 7.78 (m, 2H), 
7.64 – 7.34 (m, 6H), 7.21 – 7.11 (m, 2H), 7.03 (t, J = 7.2 
Hz, 1H), 6.96 (s, 1H), 3.86 (s, 3H). 13C{1H} NMR (75 
MHz, DMSO-d6) δ = 142.3 (Cq), 139.9 (Cq), 138.2 
(Cq), 137.9 (Cq), 137.2 (Cq), 127.4 (Cq), 125.0 (CH), 
124.8 (CH), 123.8 (CH), 123.7 (CH), 123.6 (CH), 122.3 
(CH), 121.7 (CH), 120.0 (CH), 119.7 (CH), 119.0 (CH), 
109.8 (CH), 99.4 (CH), 29.7 (CH3). IR (neat): 2928, 
1531, 1469, 1347, 1154 cm-1. HRMS (ESI): m/z [M+H]+ 
calcd for C19H16NS: 290.1003; found: 290.1003. 
(E)-1-(4-(2-(1-Methyl-5-(1-(3,4,5-trimethoxyphenyl) 
vinyl)-1H-indol-2-yl)vinyl)phenyl)-ethan-1-one (1a) 
Yellow solid, mp 170.1 – 170.5 °C, yield 55%, 128.6 mg. 
1H NMR (300 MHz, CDCl3) δ = 7.90 (d, J = 8.2 Hz, 2H), 
7.55 – 7.52 (m, 3H), 7.25 – 7.10 (m, 4H), 6.78 (s, 1H), 
6.55 (s, 2H), 5.38 (s, 1H), 5.31 (s, 1H), 3.82 (s, 3H), 3.79 
(s, 3H), 3.73 (s, 6H), 2.55 (s, 3H). 13C{1H} NMR (75 
MHz, CDCl3) δ = 197.5 (Cq), 152.9 (2 Cq), 151.0 (Cq), 
141.8 (Cq), 138.4 (Cq), 138.3 (Cq), 138.2 (Cq), 137.9 
(Cq), 136.2 (Cq), 133.7 (Cq), 129.5 (CH), 129.1 (2 CH), 
127.8 (Cq), 126.5 (2 CH), 123.4 (CH), 120.7 (CH), 119.6 
(CH), 112.7 (CH2), 109.0 (CH), 105.9 (2 CH), 100.5 
(CH), 61.1 (CH3), 56.3 (2 CH3), 30.3 (CH3), 26.7 (CH3). 
IR (neat): 2936, 1678, 1598, 1579, 1504, 1392 cm-1. 
HRMS (ESI): m/z [M+H]+ calcd for C30H30NO4: 
468.2175; found: 468.2192. 
(E)-2-(4-Fluorostyryl)-1-methyl-5-(1-(3,4,5-trimethoxy 
phenyl)vinyl)-1H-indole (1b) 
Yellow solid, mp 151.6 – 151.8 °C, yield 58%, 128.6 mg. 
1H NMR (300 MHz, acetone-d6) δ = 7.74 – 7.69 (m, 2H), 
7.54 (s, 1H), 7.44 – 7.26 (m, 3H), 7.26 – 7.06 (m, 3H), 
6.86 (s, 1H), 6.67 (s, 2H), 5.42 (s, 1H), 5.40 (s, 1H), 3.92 
(s, 3H), 3.78 (s, 3H), 3.77 (s, 6H). 13C{1H} NMR (75 
MHz, acetone-d6) δ = 163.2 (d, J = 244.1 Hz, Cq), 154.0 
(2 Cq), 152.2 (Cq), 140.0 (Cq), 139.1 (Cq), 139.0 (Cq), 
138.9 (Cq), 134.8 (d, J = 3.2 Hz, Cq), 134.0 (Cq), 130.3 
(CH), 129.2 (d, J = 7.9 Hz, 2 CH), 128.9 (Cq), 123.2 
(CH), 120.8 (CH), 118.0 (CH), 116.3 (d, J = 21.7 Hz, 2 
CH), 112.5 (CH2), 109.9 (CH), 106.9 (2 CH), 99.8 (CH), 
60.6 (CH3), 56.4 (2 CH3), 30.2 (CH3). 19F NMR (188 
MHz, acetone-d6): δ = -113.558. IR (neat): 2937, 1631, 
1505, 1462, 1391, 1277, 1260, 1235 cm-1. HRMS (ESI): 
m/z [M+H]+ calcd for C28H27NO3F: 444.1975; found: 
444.1973. 
(E)-2-(4-Methoxystyryl)-1-methyl-5-(1-(3,4,5-trimetho 
xyphenyl)vinyl)-1H-indole (1c) 
Yellow solid, mp 159.7 – 159.9 °C, yield 61%, 136.7 mg. 
1H NMR (300 MHz, CDCl3) δ = 7.61 (s, 1H), 7.50 (d, J = 
8.4 Hz, 2H), 7.30 – 7.14 (m, 3H), 7.10 – 6.89 (m, 3H), 
6.77 (s, 1H), 6.67 (s, 2H), 5.48 (s, 1H), 5.41 (s, 1H), 3.93 
(s, 3H), 3.87 – 3.83 (m, 12H). 13C{1H} NMR (75 MHz, 
CDCl3) δ = 159.7 (Cq), 152.9 (2 Cq), 151.2 (Cq), 139.6 
(Cq), 138.4 (Cq), 138.0 (Cq), 137.8 (Cq), 133.3 (Cq), 
130.9 (CH), 130.0 (Cq), 128.0 (Cq), 127.8 (2 CH), 122.5 
(CH), 120.3 (CH), 114.8 (CH), 114.3 (2 CH), 112.5 
(CH2), 108.7 (CH), 105.9 (2 CH), 98.7 (CH), 61.0 (CH3), 
56.2 (2 CH3), 55.4 (CH3), 30.1 (CH3). IR (neat): 2935, 
1766, 1604, 1578, 1508, 1464, 1348, 1252 cm-1. HRMS 
(ESI): m/z [M+H]+ calcd for C29H30NO4: 456.2175; 
found: 456.2189. 
(E)-1-Methyl-5-(1-(3,4,5-trimethoxyphenyl)vinyl)-2-
(4-vinylstyryl)-1H-indole (1d) 
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Yellow solid, mp 139.4 – 139.8 °C, yield 63%, 142.2 mg. 
1H NMR (300 MHz, acetone-d6) δ = 7.64 (d, J = 8.1 Hz, 
2H), 7.56 – 7.26 (m, 6H), 7.19 (dd, J = 8.4 Hz, J = 1.5 
Hz, 1H), 6.88 (s, 1H), 6.78 (dd, J = 17.7 Hz, J = 11.1 Hz, 
1H), 6.68 (s, 2H), 5.85 (d, J = 17.7 Hz, 1H), 5.41 (d, J = 
4.8 Hz, 2H), 5.26 (d, J = 11.1 Hz, 1H), 3.91 (s, 3H), 3.78 
(s, 3H), 3.77 (s, 6H). 13C{1H} NMR (75 MHz, acetone-
d6) δ = 154.0 (2 Cq), 152.2 (Cq), 140.1 (Cq), 139.1 (Cq), 
139.0 (Cq), 138.9 (Cq), 137.9 (2 Cq), 137.4 (CH), 134.0 
(Cq), 131.1 (CH), 128.9 (Cq), 127.6 (2 CH), 127.4 (2 
CH), 123.3 (CH), 120.8 (CH), 118.0 (CH), 114.1 (CH2), 
112.5 (CH2), 109.9 (CH), 106.9 (2 CH), 99.9 (CH), 60.6 
(CH3), 56.4 (2 CH3), 30.2 (CH3). IR (neat): 2935, 1579, 
1504, 1463, 1449, 1348 cm-1. HRMS (ESI): m/z [M+H]+ 
calcd for C30H30NO3: 452.2226; found: 452.2223. 
(E)-1-Methyl-2-(3-nitrostyryl)-5-(1-(3,4,5-trimethoxy 
phenyl)vinyl)-1H-indole (1e) 
Yellow solid, mp 191.9 – 192.1 °C, yield 57%, 134.1 mg. 
1H NMR (300 MHz, CDCl3) δ = 8.32 (s, 1H), 8.04 (d, J = 
8.1 Hz, 1H), 7.72 (d, J = 8.1 Hz, 1H), 7.58 – 7.42 (m, 
2H), 7.28 – 7.08 (m, 4H), 6.78 (s, 1H), 6.55 (s, 2H), 5.38 
(s, 1H), 5.32 (s, 1H), 3.82 (s, 3H), 3.80 (s, 3H), 3.73 (s, 
6H). 13C{1H} NMR (75 MHz, CDCl3) δ = 152.9 (2 Cq), 
151.0 (Cq), 148.9 (Cq), 139.0 (Cq), 138.4 (Cq), 138.2 
(Cq), 137.9 (2 Cq), 133.7 (Cq), 132.5 (CH), 129.8 (CH), 
128.1 (CH), 127.7 (Cq), 123.5 (CH), 122.3 (CH), 120.7 
(CH), 120.6 (CH), 119.9 (CH), 112.7 (CH2), 109.0 (CH), 
105.9 (2 CH), 100.7 (CH), 61.1 (CH3), 56.3 (2 CH3), 
30.3 (CH3). IR (neat): 2936, 1630, 1578, 1529, 1504, 
1465, 1349 cm-1. HRMS (ESI): m/z [M+H]+ calcd for 
C28H27N2O5: 471.1920; found: 471.1924. 
(E)-1-Methyl-2-styryl-5-(1-(3,4,5-trimethoxy 
phenyl)vinyl)-1H-indole (1f) 
Yellow solid, mp 121.0 – 121.3 °C, yield 60%, 127.6 mg. 
1H NMR (300 MHz, acetone-d6) δ = 7.67 (d, J = 7.2 Hz, 
2H), 7.54 – 7.29 (m, 7H), 7.19 (d, J = 8.7 Hz, 1H), 6.88 
(s, 1H), 6.67 (s, 2H), 5.41 (s, 1H), 5.39 (s, 1H), 3.93 (s, 
3H), 3.78 (s, 9H). 13C{1H} NMR (75 MHz, acetone-d6) 
δ = 153.1 (2 Cq), 151.3 (Cq), 139.2 (Cq), 138.2 (Cq), 
138.1 (Cq), 138.0 (Cq), 137.4 (Cq), 133.1 (Cq), 130.6 
(CH), 128.7 (2 CH), 128.0 (Cq), 127.7 (CH), 126.5 (2 
CH), 122.3 (CH), 119.9 (CH), 117.1 (CH), 111.6 (CH2), 
108.9 (CH), 106.0 (2 CH), 98.9 (CH), 59.7 (CH3), 55.5 
(2 CH3), 29.3 (CH3). IR (neat): 1579, 1503, 1463, 1449, 
1411, 1348, 1236 cm-1. HRMS (ESI): m/z [M+H]+ calcd 
for C28H28NO3: 426.2069; found: 426.2065. 
(E)-3-(2-(1-Methyl-5-(1-(3,4,5-
trimethoxyphenyl)vinyl)-1H-indol-2-yl)vinyl)aniline 
(1g) 
Yellow solid, mp 95.6 – 95.8 °C, yield 58%, 127.8 mg. 
1H NMR (300 MHz, acetone-d6) δ = 7.52 (s, 1H), 7.39 – 
7.05 (m, 5H), 6.96 – 6.83 (m, 3H), 6.71 – 6.58 (m, 3H), 
5.41 (s, 1H), 5.39 (s, 1H), 4.68 (br, 2H), 3.90 (s, 3H), 
3.78 (s, 9H). 13C{1H} NMR (75 MHz, acetone-d6) δ = 
153.1 (2 Cq), 151.3 (Cq), 148.7 (Cq), 139.4 (Cq), 139.1 
(Cq), 138.2 (Cq), 138.0 (Cq), 137.9 (Cq), 133.0 (Cq), 
131.6 (CH), 129.2 (CH), 128.0 (Cq), 122.1 (CH), 119.8 
(CH), 116.2 (CH), 115.5 (CH), 114.2 (CH), 112.2 (CH), 
111.5 (CH2), 108.9 (CH), 106.0 (2 CH), 98.6 (CH), 59.7 
(CH3), 55.5 (2 CH3), one CH3 peak was buried in the 
solvent signals. IR (neat): 3450, 2396, 1599, 1579, 1503, 
1463, 1412, 1348 cm-1. HRMS (ESI): m/z [M+H]+ calcd 
for C28H29N2O3: 441.2178; found: 441.2180. 
(E)-1-(4-(2-(1-Methyl-5-(methyl(3,4,5-trimethoxy 
phenyl)amino)-1H-indol-2-yl)vinyl)phenyl)ethan-1-
one (2a) 
Yellow solid, mp 212.8 – 213.0 °C, yield 77%, 181.2 mg. 
1H NMR (300 MHz, CDCl3) δ = 7.99 (d, J = 8.4 Hz, 2H), 
7.62 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 1.8 Hz, 1H), 7.33 – 
7.20 (m, 3H), 7.07 (dd, J = 8.4 Hz, J = 1.8 Hz, 1H), 6.85 
(s, 1H), 6.08 (s, 2H), 3.87 (s, 3H), 3.82 (s, 3H), 3.76 (s, 
6H), 3.35 (s, 3H), 2.64 (s, 3H). 13C{1H} NMR (75 MHz, 
CDCl3) δ = 197.5 (Cq), 153.6 (2 Cq), 147.2 (Cq), 143.3 
(Cq), 142.5 (Cq), 141.8 (Cq), 138.5 (Cq), 136.2 (Cq), 
135.9 (Cq), 129.4 (CH), 129.1 (2 CH), 128.7 (Cq), 126.5 
(2 CH), 121.2 (CH), 119.6 (CH), 116.3 (CH), 110.2 
(CH), 100.0 (CH), 94.2 (2 CH), 61.2 (CH3), 56.2 (2 
CH3), 41.5 (CH3), 30.3 (CH3), 26.7 (CH3). IR (neat): 
2958, 1678, 1598, 1507, 1307, 1263 cm-1. HRMS (ESI): 
m/z [M+H]+ calcd for C29H31N2O4: 471.2284; found: 
471.2286. 
(E)-2-(4-Fluorostyryl)-N,1-dimethyl-N-(3,4,5-trimetho 
xyphenyl)-1H-indol-5-amine (2b) 
Yellow solid, mp 180.1 – 180.4 °C, yield 74%, 165.2 mg. 
1H NMR (300 MHz, acetone-d6) δ = 7.76 – 7.70 (m, 2H), 
7.46 – 7.28 (m, 4H), 7.21 -7.14 (m, 2H), 7.00 (d, J = 8.7 
Hz, 1H), 6.84 (s, 1H), 6.09 (s, 2H), 3.92 (s, 3H), 3.69 (s, 
6H), 3.66 (s, 3H), 3.31 (s, 3H). 13C{1H} NMR (75 MHz, 
acetone-d6) δ = 163.2 (d, J = 244.6 Hz, Cq), 154.6 (2 
Cq), 148.1 (Cq), 143.2 (Cq), 139.9 (Cq), 136.6 (Cq), 
134.9 (d, J = 3.2 Hz, Cq), 132.2 (Cq), 130.1 (CH), 129.7 
(Cq), 129.2 (d, J = 7.8 Hz, 2 CH), 121.1 (CH), 118.1 
(CH), 116.6 (d, J = 22.8 Hz, 2 CH), 116.2 (CH), 111.0 
(CH), 99.4 (CH), 95.2 (2 CH), 60.6 (CH3), 56.3 (2 CH3), 
41.6 (CH3), one CH3 peak was buried in the solvent 
signals. 19F NMR (188 MHz, acetone-d6): δ = -115.708. 
IR (neat): 2934, 1603, 1583, 1506, 1258, 1233 cm-1. 
HRMS (ESI): m/z [M+H]+ calcd for C27H28N2O3F: 
447.2084; found: 447.2085. 
(E)-2-(4-Methoxystyryl)-N,1-dimethyl-N-(3,4,5-
trimethoxyphenyl)-1H-indol-5-amine (2c) 
Yellow solid, mp 110.1 – 110.3 °C, yield 82%, 188.0 mg. 
1H NMR (300 MHz, acetone-d6) δ = 7.61 (d, J = 8.7 Hz, 
2H), 7.42 – 7.23 (m, 4H), 7.07 – 6.86 (m, 3H), 6.78 (s, 
1H), 6.09 (s, 2H), 3.89 (s, 3H), 3.84 (s, 3H), 3.68 (s, 6H), 
3.66 (s, 3H), 3.30 (s, 3H). 13C{1H} NMR (75 MHz, 
acetone-d6) δ = 160.6 (Cq), 154.5 (2 Cq), 148.1 (Cq), 
143.1 (Cq), 140.5 (Cq), 136.6 (Cq), 132.1 (Cq), 131.2 
(CH), 131.0 (Cq), 129.8 (Cq), 128.7 (2 CH), 120.9 (CH), 
116.8 (CH), 115.8 (CH), 115.0 (2 CH), 110.9 (CH), 98.7 
(CH), 95.1 (2 CH), 60.6 (CH3), 56.2 (2 CH3), 55.6 (CH3), 
41.6 (CH3). one CH3 peak was buried in the solvent 
signals. IR (neat): 2958, 1604, 1582, 1507, 1483, 1465, 
1247 cm-1. HRMS (ESI): m/z [M+H]+ calcd for 
C28H31N2O4: 459.2284; found: 459.2291. 
(E)-N,1-Dimethyl-N-(3,4,5-trimethoxyphenyl)-2-(4-
vinylstyryl)-1H-indol-5-amine (2d) 
Yellow solid, mp 133.2 – 133.6 °C, yield 80%, 181.8 mg. 
1H NMR (300 MHz, acetone-d6) δ = 7.64 (d, J = 8.4 Hz, 
2H), 7.56 – 7.24 (m, 6H), 6.99 (dd, J = 8.7 Hz, J = 2.1 
Hz, 1H), 6.93 – 6.62 (m, 2H), 6.10 (s, 2H), 5.85 (d, J = 
18.3 Hz, 1H), 5.26 (d, J = 10.8 Hz, 1H), 3.91 (s, 3H), 
3.69 (s, 6H), 3.67 (s, 3H), 3.31 (s, 3H). 13C{1H} NMR 
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(75 MHz, acetone-d6) δ = 154.6 (2 Cq), 148.1 (Cq), 
143.2 (Cq), 140.1 (Cq), 138.0 (Cq), 137.9 (Cq), 137.4 
(CH), 136.7 (Cq), 132.2 (Cq), 130.9 (CH), 129.8 (Cq), 
127.6 (2 CH), 127.4 (2 CH), 121.2 (CH), 118.1 (CH), 
116.8 (CH), 114.1 (CH2), 111.0 (CH), 99.5 (CH), 95.3 (2 
CH), 60.6 (CH3), 56.3 (2 CH3), 41.6 (CH3), 30.2 (CH3). 
IR (neat): 2935, 1603, 1582, 1506, 1482, 1465, 1450, 
1258 cm-1. HRMS (ESI): m/z [M+H]+ calcd for 
C29H31N2O3: 455.2335; found: 455.2336. 
Procedure for the synthesis of 4-bromo-N,N-dimethyl-
2-((trimethylsilyl)ethynyl)aniline 6. 
To a stirred mixture of 4-bromo-2-iodo-N,N-
dimethylaniline (20 mmol), PdCl2(PPh3)2 (0.05 equiv) 
and CuI (0.1 equiv) in Et3N (50 mL), 
trimethylsilylacetylene (1.1 equiv, 3.3 mL) was added 
dropwise at 0 °C. The mixture was then stirred at room 
temperature. When the starting material was disappeared 
(TLC monitoring), the mixture was passed through a pad 
of Celite to remove the insoluble materials. The filtrate 
was concentrated in vacuo and the residue was purified 
by silica gel column chromatography (0 to 10% AcOEt in 
cyclohexane). 
4-bromo-N,N-dimethyl-2-((trimethylsilyl)ethynyl) 
aniline (6) 
Colorless oil, yield 91%, 5.33 g. 
1H NMR (300 MHz, CDCl3) δ = 7.29 (d, J = 2.4 Hz, 1H), 
7.06 (dd, J = 9.0 Hz, J = 2.5 Hz, 1H), 6.48 (d, J = 9.0 Hz, 
1H), 2.70 (s, 6H), 0.03 (s, 9H). 13C{1H} NMR (75 MHz, 
CDCl3) δ = 154.2 (Cq), 137.0 (CH), 132.3 (CH), 118.3 
(CH), 116.4 (Cq), 111.8 (Cq), 103.2 (Cq), 101.2 (Cq), 
43.3 (2 CH3), 0 (3 CH3). IR (neat): 2958, 2838, 2151, 
1488, 1386, 838 cm-1. HRMS (ESI): m/z [M+H]+ calcd 
for C13H19N79BrSi: 296.0470; found: 296.0469. 
Procedure for the synthesis of 8. 
A 50 mL flask was charged with aryl halide 6 (10 mmol), 
Xphos (10 mol%), Pd2dba3 (5 mol%), LiOtBu (2.2 equiv), 
the tosylhydrazone 7 (1.2 equiv) and dioxane (25 mL). 
The system was stirred at 70º with monitored by TLC 
analysis. When the reaction was completed, the crude 
reaction mixture was allowed to cool to room 
temperature and filtered through celite washed by CH2Cl2. 
The solvents were evaporated under reduced pressure, 
and the residue was purified by silica gel column 
chromatography (0 to 20% AcOEt in cyclohexane). 
N,N-Dimethyl-4-(1-(3,4,5-trimethoxyphenyl)vinyl)-2-
((trimethylsilyl)ethynyl)aniline (8) 
Brown oil, yield 86%, 3.52 g. 
1H NMR (300 MHz, CDCl3) δ = 7.47 (d, J = 1.8 Hz, 1H), 
7.17 (dd, J = 8.7 Hz, J = 1.8 Hz, 1H), 6.79 (d, J = 8.4 Hz, 
1H), 6.55 (s, 2H), 5.36 (s, 1H), 5.30 (s, 1H), 3.88 (s, 3H), 
3.81 (s, 6H), 2.99 (s, 6H), 0.26 (s, 9H). 13C{1H} NMR 
(75 MHz, CDCl3) δ = 154.8 (Cq), 153.0 (2 Cq), 149.1 
(Cq), 137.9 (Cq), 137.4 (Cq), 134.6 (CH), 132.9 (Cq), 
129.6 (CH), 116.3 (CH), 114.8 (Cq), 113.9 (Cq), 112.6 
(CH2), 105.8 (2 CH), 104.7 (Cq), 61.0 (CH3), 56.3 (2 
CH3), 43.3 (2 CH3), 0.1 (3 CH3). IR (neat): 2999, 2957, 
2835, 2786, 2148, 1598, 1503, 1465, 1347 842 cm-1. 
HRMS (ESI): m/z [M+H]+ calcd for C24H32NO3Si: 
410.2151; found: 410.2149. 
Procedure for the synthesis of 10. 
Aryl bromine 6 (1 mmol) (note: the yiled will drastically 
decrease when increasing the quantity of starting 
material), Xphos (10 mol%), Pd2dba3 (5 mol%), NaOtBu 
(2.2 equiv), 3,4,5-trimethoxy-N-methylaniline (1.2 equiv) 
were mixed in 8 mL of toluene. The system was stirred at 
70º in a 30 mL sealed tube with monitored by TLC 
analysis. When the reaction was completed, the crude 
reaction mixture was allowed to cool to room 
temperature and filtered through celite washed by CH2Cl2. 
The solvents were evaporated under reduced pressure, 
and the residue was purified by silica gel column 
chromatography (0 to 20% AcOEt in cyclohexane). 
N1,N1,N4-Trimethyl-N4-(3,4,5-trimethoxyphenyl)-2-
((trimethylsilyl)ethynyl)benzene-1,4-diamine (10) 
Brown oil, yield 83%, 342.5 mg. 
1H NMR (300 MHz, acetone-d6) δ = 7.06 – 6.87 (m, 3H), 
6.21 (s, 2H), 3.73 (s, 6H), 3.67 (s, 3H), 3.21 (s, 3H), 2.88 
(s, 6H), 0.22 (s, 9H). 13C{1H} NMR (75 MHz, acetone-
d6) δ = 154.9 (2 Cq), 154.1 (Cq), 151.6 (Cq), 146.9 (Cq), 
143.6 (Cq), 128.2 (CH), 124.7 (CH), 119.0 (CH), 116.7 
(Cq), 105.9 (Cq), 99.6 (Cq), 98.6 (2 CH), 60.8 (CH3), 
56.5 (2 CH3), 43.9 (2 CH3), 41.1 (CH3), 0.2 (3 CH3). IR 
(neat): 2958, 2783, 2149, 1715, 1611, 1496, 1247, 841 
cm-1. HRMS (ESI): m/z [M+H]+ calcd for C23H33N2O3Si: 
413.2260; found: 413.2266. 
Procedure for the Synthesis of terminal alkyne 9, 11. 
To an oven dried 100 mL round-bottomed flask was 
added 2-((trimethylsilyl)ethynyl)aniline (5 mmol), MeOH 
(30 mL), and oven dried K2CO3 (1 equiv). The flask was 
stirred under argon atmosphere at room temperature. 
When TLC show the disappearance of starting material, 
H2O (30 mL) was added to the flask. After extracted with 
CH2Cl2 (3 × 30 mL), the organic layer was dried over 
anhydrous MgSO4, and concentrated in vacuo. The crude 
oil was then purified by column chromatography on silica 
gel (0 to 20% AcOEt in cyclohexane). 
2-Ethynyl-N,N-dimethyl-4-(1-(3,4,5-trimethoxy 
phenyl)vinyl)aniline (9) 
Brown oil, yield 92%, 1.55 g. 
1H NMR (300 MHz, CDCl3) δ = 7.41 (d, J = 2.1 Hz, 1H), 
7.18 – 7.14 (m, 1H), 6.79 (d, J = 8.7 Hz, 1H), 6.47 (s, 
2H), 5.30 (s, 1H), 5.24 (s, 1H), 3.81 (s, 3H), 3.75 (s, 6H), 
3.32 (s, 1H), 2.90 (s, 6H). 13C{1H} NMR (75 MHz, 
CDCl3) δ = 155.2 (Cq), 153.0 (2 Cq), 149.0 (Cq), 137.3 
(Cq), 134.8 (CH), 133.4 (Cq), 129.7 (CH), 116.7 (CH), 
113.7 (Cq), 112.9 (CH2), 112.8 (Cq), 105.8 (2 CH), 83.1 
(Cq), 82.5 (CH), 61.0 (CH3), 56.3 (2 CH3), 43.6 (2 CH3). 
IR (neat): 3276, 2957, 2836, 1599, 1579, 1464, 1451, 
1347, 1266 cm-1. HRMS (ESI): m/z [M+H]+ calcd for 
C21H24NO3: 338.1756; found: 338.1755. 
2-Ethynyl-N1,N1,N4-trimethyl-N4-(3,4,5-trimethoxy 
phenyl)benzene-1,4-diamine (11) 
Brown oil, yield 90%, 1.53 g. 
1H NMR (300 MHz, CDCl3) δ = 7.15 (d, J = 2.7 Hz, 1H), 
6.96 (dd, J = 8.7 Hz, J = 2.7 Hz, 1H), 6.87 (d, J = 8.7 Hz, 
1H), 6.15 (s, 2H), 3.81 (s, 3H), 3.77 (s, 6H), 3.38 (s, 1H), 
3.23 (s, 3H), 2.89 (s, 6H). 13C{1H} NMR (75 MHz, 
CDCl3) δ = 153.7 (2 Cq), 150.6 (Cq), 145.7 (Cq), 142.9 
(Cq), 132.8 (Cq), 127.5 (CH), 123.3 (CH), 118.3 (CH), 
115.8 (Cq), 97.5 (2 CH), 82.7 (Cq), 82.3 (CH), 61.1 
(CH3), 56.2 (2 CH3), 44.2 (2 CH3), 40.8 (CH3). IR (neat): 
2937, 2826, 1612, 1495, 1450, 1309, 1236 cm-1. HRMS 
(ESI): m/z [M+H]+ calcd for C20H25N2O3: 341.1865; 
found: 341.1870. 
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Supporting Information: 
Supporting Information contains copies of 1H, 13C and 
19F NMR spectra of new compounds.  
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